- Home
- BRSP vs ALT Comparison
BRSP vs ALT Comparison
Compare BRSP & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRSP
- ALT
- Stock Information
- Founded
- BRSP 2017
- ALT 1997
- Country
- BRSP United States
- ALT United States
- Employees
- BRSP N/A
- ALT N/A
- Industry
- BRSP Real Estate Investment Trusts
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- BRSP Real Estate
- ALT Health Care
- Exchange
- BRSP Nasdaq
- ALT Nasdaq
- Market Cap
- BRSP 561.8M
- ALT 472.3M
- IPO Year
- BRSP 2018
- ALT N/A
- Fundamental
- Price
- BRSP $4.67
- ALT $4.97
- Analyst Decision
- BRSP Buy
- ALT Strong Buy
- Analyst Count
- BRSP 5
- ALT 8
- Target Price
- BRSP $6.88
- ALT $21.00
- AVG Volume (30 Days)
- BRSP 888.9K
- ALT 2.2M
- Earning Date
- BRSP 04-29-2025
- ALT 05-08-2025
- Dividend Yield
- BRSP 13.62%
- ALT N/A
- EPS Growth
- BRSP N/A
- ALT N/A
- EPS
- BRSP N/A
- ALT N/A
- Revenue
- BRSP $358,805,000.00
- ALT $20,000.00
- Revenue This Year
- BRSP N/A
- ALT N/A
- Revenue Next Year
- BRSP $25.80
- ALT N/A
- P/E Ratio
- BRSP N/A
- ALT N/A
- Revenue Growth
- BRSP N/A
- ALT N/A
- 52 Week Low
- BRSP $4.16
- ALT $3.55
- 52 Week High
- BRSP $6.71
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- BRSP 37.52
- ALT 51.06
- Support Level
- BRSP $4.37
- ALT $4.32
- Resistance Level
- BRSP $4.53
- ALT $4.75
- Average True Range (ATR)
- BRSP 0.25
- ALT 0.38
- MACD
- BRSP 0.01
- ALT 0.12
- Stochastic Oscillator
- BRSP 37.13
- ALT 84.75
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.